How Adolescents with Autism Spectrum Disorder (ASD) Spontaneously Attend to Real-World Scenes : Use of a Change Blindness Paradigm Michal Hochhauser, Adi Aran, Ouriel Grynszpan Journal of Autism and Developmental Disorders, 2018, 48, 502–510 DOI 10.1007/s10803-017-3343-6 https://www.researchgate.net/publication/320647151_How_Adolescents_with_Autism_Spectrum_Disorder_ASD_Spontaneously_Attend_to_Real-World_Scenes_Use_of_a_Change_Blindness_Paradigm [accessed Jul 16 2019]. Abstract Visual attention of adolescents with autism spectrum disorder (ASD) was assessed using a change blind-ness paradigm. Twenty-five adolescents with ASD aged 12–18 years and 25 matched typically developing (TD) adolescents viewed 36 pairs of digitized real-world images. Each pair of images was displayed in a ‘flicker paradigm’ whereby a particular item alternately appeared and disappeared. This item was either a central or a marginal [...]
Lire la suiteIbogaine and Subjective Experience : Transformative States and Psychopharmacotherapy in the Treatment of Opioid Use Disorder Thomas K. Brown, PhDa, Geoff E. Noller, PhDb, and Julie O. Denenberg, MAc Journal of Psychoactive Drugs, 2019 https://doi.org/10.1080/02791072.2019.1598603 ABSTRACT This article examines the therapeutic potential of ibogaine, a powerful oneiric alkaloid derived from Tabernanthe iboga, through exploring the subjective experiences of 44 participants from two observational treatment studies for opioid use disorder. Following treatment with ibogaine HCl, the participants (Mexico, n = 30; New Zealand, n = 14) completed the States of Consciousness Questionnaire (SCQ) to quantify the magnitude of their psychotropic experience. Participants were asked to provide [...]
Lire la suiteLe cannabidiol en traitement «anti-addictif» chez les patients alcooliques : l’étude CARAMEL PHRC-N 2018 n°0198 Investigateur principal B. Rolland François Bailly, service d’hépatologie et d’addictologie, Hôpital de la Croix Rousse, Lyon. Le cannabidiol en traitement « anti-addictif » chez les patients alcooliques : l’étude CARAMEL François Bailly Hôpital de la Croix-Rousse, Lyon Le protocole CARAMEL, qui devrait démarrer début 2020, est destiné à étudier l’intérêt du cannabidiol dans la dépendance alcoolique. Le projet d’étude est centré sur les effets du CBD sur le système nerveux central et les neuroprotecteurs et antioxydants, qui ont un impact sur la toxicité de l’alcool au niveau du cerveau et du foie, [...]
Lire la suiteUTILISATION DU DRONABINOL (MARINOL ®) EN FRANCE Dr Sarah Lejczak AH, CETD, CHU Nantes sarah.lejczak@chu-nantes.fr 20.06.2019 Utilisation du Marinol en France : enquête auprès des prescripteurs Sarah Lejczak CHU de Nantes Sarah Lejczak, médecin algologue, rappelle qu’il est possible de prescrire du Marinol depuis 2006. Le premier essai clinique sur le cannabis thérapeutique a été réalisé au XIXe siècle, avec des patients atteints de choléra et de tétanos. Ces essais ont été suivis de dérives et de périodes de prohibition. Fort heureusement, des équipes de chercheurs se sont de nouveau emparées de ce sujet à partir des années 1970. Aux États-Unis, l’approche de ce sujet diverge selon les États. [...]
Lire la suiteRetrouvez l’ensemble des interventions des 24es Rencontres du RESPADD - GRECC : Utilisation cliniques des cannabinoïdes, juin 2019 Sarah LEJCZAK "Utilisation du Marinol en France : enquête auprès des prescripteurs" Roland TUBIANA et Fabienne CABY "Infection VIH et cannabinoïdes, état des lieux et pistes en recherche clinique" Allison McKIM : "Addicted to rehab : race, gender and drugs in the era of mass incarceration" Fabrice Olivet : "Races et drogues, les termes du sujet" François BAILLY : "Le cannabidiol en traitement "anti-addictif" chez les patients alcooliques : l'étude Caramel" Julien AZUAR "Usage de CBD et maladie psychiatrique" Pierre CHAMPY : "Cannabis sativa, plante médicinale en France ?" Jean-Michel [...]
Lire la suitePsychedelic Cuts Cravings, Consumption in Alcohol Use Disorder Pauline Anderson Medscape, May 23, 2019 https://www.medscape.com/viewarticle/913422?src=wnl_tp10n_190711_mscpedit&uac=292598PZ&impID=2023688&faf=1 SAN FRANCISCO — Just two doses of the psychedelic drug psilocybin, taken over a period of 8 weeks, significantly reduced alcohol use and cravings in patients with alcohol use disorder, preliminary findings show. In the first study to use modern clinical trial design to investigate the effects of a hallucinogen in alcohol-dependent patients, investigators at New York University (NYU) School of Medicine in New York City found that use of psilocybin was significantly associated with fewer drinking days and fewer drinks per day, as well fewer cravings. Dr Kelley Clark O'Donnell "Psychedelic [...]
Lire la suiteCannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia : A Multicenter Randomized Controlled Trial Philip McGuire, F.R.C.Psych., F.Med.Sci., Philip Robson, M.R.C.P., F.R.C.Psych., Wieslaw Jerzy Cubala, M.D., Ph.D., Daniel Vasile, M.D., Ph.D., Paul Dugald Morrison, Ph.D., M.R.C.Psych., Rachel Barron, B.Vet.Med., M.R.C.V.S., Adam Taylor, Ph.D., Stephen Wright, F.R.C.P.(Edin), F.F.P.M. American Journal of Psychiatry, 2018, 175, 225–231. doi: 10.1176/appi.ajp.2017.17030325 Objective : Research in both animals and humans indicates that cannabidiol (CBD) has antipsychotic properties. The authors assessed the safety and effectiveness of CBD in patients with schizophrenia. Method : In an exploratory double-blind parallel-group trial, patients with schizophrenia were randomized in a 1:1 ratio to receive CBD (1000 [...]
Lire la suiteCannabidiol as a Potential New Type of an Antipsychotic. A Critical Review of the Evidence Cathrin Rohleder, Juliane K. Müller, Bettina Lange and F. M. Leweke Frontiers in Pharmacology, 2016, Volume 7, Article 422. doi: 10.3389/fphar.2016.00422 There is urgent need for the development of mechanistically different and less side-effect prone antipsychotic compounds. The endocannabinoid system has been suggested to represent a potential new target in this indication. While the chronic use of cannabis itself has been considered a risk factor contributing to the development of schizophrenia, triggered by the phytocannabinoid delta-9-tetra-hydro-cannabinol (19-THC), cannabidiol, the second most important phytocannabinoid, appears to have no psychotomimetic potential. [...]
Lire la suitePsilocybin and Mental Health–Don’t Lose Control (Opinion) Joseph M. Barnby and Mitul A. Mehta Frontiers in Psychiatry, published: 03 July 2018 | Volume 9 | Article 293 doi: 10.3389/fpsyt.2018.00293 Keywords : psychedelics, psilocybin, depression, clinical trials, methodology Psilocybin—the hallucinogenic pro-drug in magic mushrooms—has recently dominated the popular narrative on new approaches to treating depression. For example, recent papers from John’s Hopkins (1) and Imperial College (2, 3) demonstrate the potential for psilocybin to promote positive lifestyle changes, and as an intervention for treatment-resistant depression, respectively. They also provide an opportunity to highlight two recurrent issues with psychedelic research which we place in the context of more [...]
Lire la suiteTherapeutic Potential of Cannabinoids in Psychosis. Leweke F.M., Mueller J.K., Lange B., Rohleder C. Biological Psychiatry, 2016, 79, (7) 604-612. doi: 10.1016/j.biopsych.2015.11.018. Abstract Over recent years, the interest in the endocannabinoid system (ECS) as a new target for the treatment of schizophrenia has evolved. The ECS represents one of the most relevant neurotransmitter systems in the brain and mainly fulfills a homeostatic role in terms of neurotransmission but also with respect to inflammatory processes. Two main approaches to the modulation of endocannabinoid functioning have been chosen so far. First, the selective blockade or inverse agonism of the type 1 cannabinoid receptor has been tested for [...]
Lire la suite